

Jason S Carroll

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8925131/publications.pdf>

Version: 2024-02-01

144
papers

21,285
citations

15495

65
h-index

10441

139
g-index

169
all docs

169
docs citations

169
times ranked

27502
citing authors

#	ARTICLE	IF	CITATIONS
1	ETV6-RUNX1 and RUNX1 directly regulate RAG1 expression: one more step in the understanding of childhood B-cell acute lymphoblastic leukemia leukemogenesis. <i>Leukemia</i> , 2022, 36, 549-554.	3.3	11
2	ncRNAseq: simple modifications to RNA-seq library preparation allow recovery and analysis of mid-sized non-coding RNAs. <i>BioTechniques</i> , 2022, 72, 21-28.	0.8	2
3	Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis. <i>Cancer Research</i> , 2022, 82, 1321-1339.	0.4	30
4	Divinylpyrimidine reagents generate antibody drug conjugates with excellent <i>in vivo</i> efficacy and tolerability. <i>Chemical Communications</i> , 2022, 58, 1962-1965.	2.2	10
5	Estrogen receptor beta repurposes EZH2 to suppress oncogenic NF κ B/p65 signaling in triple negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 20.	2.3	9
6	Elevated ASCL1 activity creates de novo regulatory elements associated with neuronal differentiation. <i>BMC Genomics</i> , 2022, 23, 255.	1.2	15
7	The renal lineage factor PAX8 controls oncogenic signalling in kidney cancer. <i>Nature</i> , 2022, 606, 999-1006.	13.7	24
8	Site-selective modification strategies in antibody drug conjugates. <i>Chemical Society Reviews</i> , 2021, 50, 1305-1353.	18.7	207
9	Genome-Wide Estrogen Receptor Activity in Breast Cancer. <i>Endocrinology</i> , 2021, 162, .	1.4	28
10	Rapid and robust cysteine bioconjugation with vinylheteroarenes. <i>Chemical Science</i> , 2021, 12, 9060-9068.	3.7	14
11	The androgen receptor is a tumor suppressor in estrogen receptor positive breast cancer. <i>Nature Medicine</i> , 2021, 27, 310-320.	15.2	122
12	Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype. <i>Oncogene</i> , 2021, 40, 1318-1331.	2.6	10
13	TET2 is a component of the estrogen receptor complex and controls 5mC to 5hmC conversion at estrogen receptor cis-regulatory regions. <i>Cell Reports</i> , 2021, 34, 108776.	2.9	20
14	Reduction of RUNX1 transcription factor activity by a CBFA2T3-mimicking peptide: application to B cell precursor acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2021, 14, 47.	6.9	7
15	Enhancer recruitment of transcription repressors RUNX1 and TLE3 by mis-expressed FOXC1 blocks differentiation in acute myeloid leukemia. <i>Cell Reports</i> , 2021, 36, 109725.	2.9	15
16	A dual-enzyme cleavable linker for antibody drug conjugates. <i>Chemical Communications</i> , 2021, 57, 3457-3460.	2.2	16
17	Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. <i>Nature Communications</i> , 2021, 12, 6377.	5.8	16
18	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	9.4	120

#	ARTICLE	IF	CITATIONS
19	ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response. <i>Nature Genetics</i> , 2020, 52, 187-197.	9.4	108
20	ELF5 modulates the estrogen receptor cistrome in breast cancer. <i>PLoS Genetics</i> , 2020, 16, e1008531.	1.5	17
21	Targeting LSD1 and FOXA1 in prostate cancer. <i>Nature Genetics</i> , 2020, 52, 1002-1003.	9.4	2
22	Dephosphorylation of the Proneural Transcription Factor ASCL1 Re-Engages a Latent Post-Mitotic Differentiation Program in Neuroblastoma. <i>Molecular Cancer Research</i> , 2020, 18, 1759-1766.	1.5	14
23	IL6/STAT3 Signaling Hijacks Estrogen Receptor Enhancers to Drive Breast Cancer Metastasis. <i>Cancer Cell</i> , 2020, 38, 412-423.e9.	7.7	145
24	Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 126.	2.2	14
25	Expeditious Total Synthesis of Hemiasterlin through a Convergent Multicomponent Strategy and Its Use in Targeted Cancer Therapeutics. <i>Angewandte Chemie</i> , 2020, 132, 23245-23250.	1.6	0
26	The proapoptotic gene interferon regulatory factor-1 mediates the antiproliferative outcome of paired box 2 gene and tamoxifen. <i>Oncogene</i> , 2020, 39, 6300-6312.	2.6	3
27	Expeditious Total Synthesis of Hemiasterlin through a Convergent Multicomponent Strategy and Its Use in Targeted Cancer Therapeutics. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 23045-23050.	7.2	14
28	General dual functionalisation of biomacromolecules via a cysteine bridging strategy. <i>Organic and Biomolecular Chemistry</i> , 2020, 18, 4224-4230.	1.5	19
29	The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver. <i>Oncogene</i> , 2020, 39, 5455-5467.	2.6	12
30	Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. <i>Molecular Cell</i> , 2020, 78, 1096-1113.e8.	4.5	114
31	Sulfatase-cleavable linkers for antibody-drug conjugates. <i>Chemical Science</i> , 2020, 11, 2375-2380.	3.7	40
32	ELF5 modulates the estrogen receptor cistrome in breast cancer. , 2020, 16, e1008531.		0
33	ELF5 modulates the estrogen receptor cistrome in breast cancer. , 2020, 16, e1008531.		0
34	ELF5 modulates the estrogen receptor cistrome in breast cancer. , 2020, 16, e1008531.		0
35	ELF5 modulates the estrogen receptor cistrome in breast cancer. , 2020, 16, e1008531.		0
36	A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody-drug conjugates. <i>Chemical Science</i> , 2019, 10, 694-700.	3.7	85

#	ARTICLE	IF	CITATIONS
37	<i>EN1</i> Is a Transcriptional Dependency in Triple-Negative Breast Cancer Associated with Brain Metastasis. <i>Cancer Research</i> , 2019, 79, 4173-4183.	0.4	47
38	Identification of ChIP-seq and RIME grade antibodies for Estrogen Receptor alpha. <i>PLoS ONE</i> , 2019, 14, e0215340.	1.1	9
39	Comprehensive Genomic Analysis Reveals that the Pioneering Function of FOXA1 Is Independent of Hormonal Signaling. <i>Cell Reports</i> , 2019, 26, 2558-2565.e3.	2.9	49
40	Progesterone Receptor Attenuates STAT1-Mediated IFN Signaling in Breast Cancer. <i>Journal of Immunology</i> , 2019, 202, 3076-3086.	0.4	29
41	Analysis of HER2 genomic binding in breast cancer cells identifies a global role in direct gene regulation. <i>PLoS ONE</i> , 2019, 14, e0225180.	1.1	9
42	A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer. <i>Oncogene</i> , 2019, 38, 1136-1150.	2.6	15
43	Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 908-920.	1.9	119
44	Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer. <i>Oncogene</i> , 2018, 37, 2008-2021.	2.6	23
45	ER β -mediated induction of cystatins results in suppression of TGF β signaling and inhibition of triple-negative breast cancer metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E9580-E9589.	3.3	47
46	Interplay between transcription regulators RUNX1 and FUBP1 activates an enhancer of the oncogene KIT and amplifies cell proliferation. <i>Nucleic Acids Research</i> , 2018, 46, 11214-11228.	6.5	28
47	Signaling pathways and steroid receptors modulating estrogen receptor function in breast cancer. <i>Genes and Development</i> , 2018, 32, 1141-1154.	2.7	107
48	Tamoxifen-Induced Apoptosis of MCF-7 Cells via GPR30/PI3K/MAPKs Interactions: Verification by ODE Modeling and RNA Sequencing. <i>Frontiers in Physiology</i> , 2018, 9, 907.	1.3	40
49	A patient-derived explant (PDE) model of hormone-dependent cancer. <i>Molecular Oncology</i> , 2018, 12, 1608-1622.	2.1	94
50	A quantitative mass spectrometry-based approach to monitor the dynamics of endogenous chromatin-associated protein complexes. <i>Nature Communications</i> , 2018, 9, 2311.	5.8	104
51	The logic of transcriptional regulator recruitment architecture at cis-regulatory modules controlling liver functions. <i>Genome Research</i> , 2017, 27, 985-996.	2.4	22
52	Embryonic transcription factor SOX9 drives breast cancer endocrine resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E4482-E4491.	3.3	83
53	Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 3417-3430.	0.4	79
54	ERR α induces H3K9 demethylation by LSD1 to promote cell invasion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3909-3914.	3.3	66

#	ARTICLE	IF	CITATIONS
55	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	13.7	1,099
56	Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. <i>Nature Communications</i> , 2017, 8, 1865.	5.8	108
57	Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity. <i>Molecular and Cellular Endocrinology</i> , 2017, 440, 138-150.	1.6	91
58	Deciphering the divergent roles of progestogens in breast cancer. <i>Nature Reviews Cancer</i> , 2017, 17, 54-64.	12.8	96
59	Pharmacological targeting of the transcription factor SOX18 delays breast cancer in mice. <i>ELife</i> , 2017, 6, .	2.8	50
60	FOXA1 Directs H3K4 Monomethylation at Enhancers via Recruitment of the Methyltransferase MLL3. <i>Cell Reports</i> , 2016, 17, 2715-2723.	2.9	122
61	Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17. <i>Cancer Research</i> , 2016, 76, 5881-5893.	0.4	50
62	Rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) for analysis of chromatin complexes. <i>Nature Protocols</i> , 2016, 11, 316-326.	5.5	235
63	Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv371.	3.0	37
64	SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 479-491.	3.2	14
65	Chromatin Immunoprecipitation-Sequencing (ChIP-seq) for Mapping of Estrogen Receptor-Chromatin Interactions in Breast Cancer. <i>Methods in Molecular Biology</i> , 2016, 1366, 79-98.	0.4	16
66	An Examination of the Association between FOXA1 Staining Level and Biochemical Recurrence following Salvage Radiation Therapy for Recurrent Prostate Cancer. <i>PLoS ONE</i> , 2016, 11, e0151785.	1.1	1
67	RIME proteomics of estrogen and progesterone receptors in breast cancer. <i>Data in Brief</i> , 2015, 5, 276-280.	0.5	7
68	Transcription factors and chromatin proteins as therapeutic targets in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 183-192.	3.3	24
69	Progesterone receptor modulates ER α action in breast cancer. <i>Nature</i> , 2015, 523, 313-317.	13.7	504
70	APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer. <i>Cell Reports</i> , 2015, 13, 108-121.	2.9	105
71	Runx2 Is a Novel Regulator of Mammary Epithelial Cell Fate in Development and Breast Cancer. <i>Cancer Research</i> , 2014, 74, 5277-5286.	0.4	60
72	Complex Formation and Function of Estrogen Receptor α in Transcription Requires RIP140. <i>Cancer Research</i> , 2014, 74, 5469-5479.	0.4	28

#	ARTICLE	IF	CITATIONS
73	Preface. <i>Molecular and Cellular Endocrinology</i> , 2014, 382, 623.	1.6	3
74	The forkhead transcription factor FOXK2 acts as a chromatin targeting factor for the BAP1-containing histone deubiquitinase complex. <i>Nucleic Acids Research</i> , 2014, 42, 6232-6242.	6.5	66
75	Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 295-309.	1.1	21
76	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. <i>Nature Communications</i> , 2014, 5, 4999.	5.8	105
77	Estrogen receptor beta in prostate cancer: friend or foe?. <i>Endocrine-Related Cancer</i> , 2014, 21, T219-T234.	1.6	85
78	Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells. <i>Genome Biology</i> , 2013, 14, R6.	13.9	113
79	A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples. <i>BMC Genomics</i> , 2013, 14, 232.	1.2	54
80	Interplay between estrogen receptor and AKT in Estradiol-induced alternative splicing. <i>BMC Medical Genomics</i> , 2013, 6, 21.	0.7	25
81	Enhancer-derived RNAs: "splicing up" transcription programs. <i>EMBO Journal</i> , 2013, 32, 2096-2098.	3.5	3
82	Endogenous Purification Reveals GREB1 as a Key Estrogen Receptor Regulatory Factor. <i>Cell Reports</i> , 2013, 3, 342-349.	2.9	319
83	FOXA1 mutations in hormone-dependent cancers. <i>Frontiers in Oncology</i> , 2013, 3, 20.	1.3	50
84	Approaches for Assessing and Discovering Protein Interactions in Cancer. <i>Molecular Cancer Research</i> , 2013, 11, 1295-1302.	1.5	7
85	Co-regulated gene expression by oestrogen receptor β and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cells. <i>Nucleic Acids Research</i> , 2013, 41, 10228-10240.	6.5	49
86	GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility. <i>Genome Research</i> , 2013, 23, 12-22.	2.4	307
87	Development of an Illumina-based ChIP-exonuclease method provides insight into FoxA1-DNA binding properties. <i>Genome Biology</i> , 2013, 14, R147.	13.9	76
88	Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. <i>EMBO Journal</i> , 2012, 31, 1617-1617.	3.5	2
89	ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast Cancer. <i>PLoS Biology</i> , 2012, 10, e1001461.	2.6	74
90	FoxA1 is a Key Mediator of Hormonal Response in Breast and Prostate Cancer. <i>Frontiers in Endocrinology</i> , 2012, 3, 68.	1.5	73

#	ARTICLE	IF	CITATIONS
91	Transducin-like enhancer protein 1 mediates estrogen receptor binding and transcriptional activity in breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2748-2753.	3.3	47
92	FOXA1 and breast cancer risk. Nature Genetics, 2012, 44, 1176-1177.	9.4	26
93	ChIPing away at breast cancer. Lancet Oncology, The, 2012, 13, 1185-1187.	5.1	5
94	Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature, 2012, 481, 389-393.	13.7	1,655
95	Pioneer factors in hormone-dependent cancers. Nature Reviews Cancer, 2012, 12, 381-385.	12.8	233
96	A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. Breast Cancer Research and Treatment, 2012, 133, 37-47.	1.1	121
97	Pioneer transcription factors: establishing competence for gene expression. Genes and Development, 2011, 25, 2227-2241.	2.7	1,388
98	FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nature Genetics, 2011, 43, 27-33.	9.4	722
99	The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cells. Breast Cancer Research and Treatment, 2011, 127, 385-396.	1.1	70
100	A co-ordinated interaction between CTCF and ER in breast cancer cells. BMC Genomics, 2011, 12, 593.	1.2	58
101	Estrogen receptor- α positive breast cancer: a multidisciplinary challenge. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2011, 3, 216-230.	6.6	24
102	<i>ZNF703</i> is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Molecular Medicine, 2011, 3, 167-180.	3.3	119
103	A Functional Variant at a Prostate Cancer Predisposition Locus at 8q24 Is Associated with PVT1 Expression. PLoS Genetics, 2011, 7, e1002165.	1.5	142
104	Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO Journal, 2011, 30, 3019-3027.	3.5	247
105	Oestrogen receptor-co-factor-chromatin specificity in the transcriptional regulation of breast cancer. EMBO Journal, 2011, 30, 4764-4776.	3.5	105
106	Growth factor stimulation induces a distinct ER α cistrome underlying breast cancer endocrine resistance. Genes and Development, 2010, 24, 2219-2227.	2.7	156
107	Cooperative interaction between retinoic acid receptor- α and estrogen receptor in breast cancer. Genes and Development, 2010, 24, 171-182.	2.7	227
108	A CTCF-independent role for cohesin in tissue-specific transcription. Genome Research, 2010, 20, 578-588.	2.4	331

#	ARTICLE	IF	CITATIONS
109	Subcellular Localization of Activated AKT in Estrogen Receptor- and Progesterone Receptor-Expressing Breast Cancers. <i>American Journal of Pathology</i> , 2010, 176, 2139-2149.	1.9	40
110	Estrogen receptor action in three dimensions - looping the loop. <i>Breast Cancer Research</i> , 2010, 12, 303.	2.2	9
111	High-throughput sequencing identifies STAT3 as the DNA-associated factor for p53 - NF-kappaB - complex-dependent gene expression in human heart failure. <i>Genome Medicine</i> , 2010, 2, 37.	3.6	32
112	Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 4260-4265.	3.3	366
113	Estrogen Regulation of Cyclin E2 Requires Cyclin D1 but Not c-Myc. <i>Molecular and Cellular Biology</i> , 2009, 29, 4623-4639.	1.1	61
114	FOXA1 Is a Potential Oncogene in Anaplastic Thyroid Carcinoma. <i>Clinical Cancer Research</i> , 2009, 15, 3680-3689.	3.2	75
115	Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer. <i>Cell</i> , 2009, 138, 245-256.	13.5	797
116	Estradiol-regulated microRNAs control estradiol response in breast cancer cells. <i>Nucleic Acids Research</i> , 2009, 37, 4850-4861.	6.5	310
117	Antiestrogens and the Cell Cycle. , 2009, , 17-45.		0
118	Regulation of ERBB2 by oestrogen receptor PAX2 determines response to tamoxifen. <i>Nature</i> , 2008, 456, 663-666.	13.7	283
119	Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. <i>EMBO Journal</i> , 2008, 27, 535-545.	3.5	279
120	xMAN: extreme MApping of OligoNucleotides. <i>BMC Genomics</i> , 2008, 9, S20.	1.2	19
121	FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription. <i>Cell</i> , 2008, 132, 958-970.	13.5	863
122	Interrogating the genome to understand oestrogen-receptor-mediated transcription. <i>Expert Reviews in Molecular Medicine</i> , 2008, 10, e10.	1.6	9
123	AKT Alters Genome-Wide Estrogen Receptor Binding and Impacts Estrogen Signaling in Breast Cancer. <i>Molecular and Cellular Biology</i> , 2008, 28, 7487-7503.	1.1	87
124	Nkx3-1 and LEF-1 Function as Transcriptional Inhibitors of Estrogen Receptor Activity. <i>Cancer Research</i> , 2008, 68, 7380-7385.	0.4	39
125	Systematic evaluation of variability in ChIP-chip experiments using predefined DNA targets. <i>Genome Research</i> , 2008, 18, 393-403.	2.4	117
126	Unique ER Cistromes Control Cell Type-Specific Gene Regulation. <i>Molecular Endocrinology</i> , 2008, 22, 2393-2406.	3.7	119

#	ARTICLE	IF	CITATIONS
127	Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3787-3792.	3.3	129
128	Positive Cross-Regulatory Loop Ties GATA-3 to Estrogen Receptor β Expression in Breast Cancer. <i>Cancer Research</i> , 2007, 67, 6477-6483.	0.4	317
129	A Hierarchical Network of Transcription Factors Governs Androgen Receptor-Dependent Prostate Cancer Growth. <i>Molecular Cell</i> , 2007, 27, 380-392.	4.5	598
130	Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. <i>Nature Reviews Cancer</i> , 2007, 7, 713-722.	12.8	191
131	p63 regulates an adhesion programme and cell survival in epithelial cells. <i>Nature Cell Biology</i> , 2006, 8, 551-561.	4.6	372
132	Genome-wide analysis of estrogen receptor binding sites. <i>Nature Genetics</i> , 2006, 38, 1289-1297.	9.4	1,227
133	Estrogen Receptor Target Gene: An Evolving Concept. <i>Molecular Endocrinology</i> , 2006, 20, 1707-1714.	3.7	249
134	A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. <i>Genes and Development</i> , 2006, 20, 2513-2526.	2.7	261
135	Model-based analysis of tiling-arrays for ChIP-chip. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 12457-12462.	3.3	390
136	Spatial and Temporal Recruitment of Androgen Receptor and Its Coactivators Involves Chromosomal Looping and Polymerase Tracking. <i>Molecular Cell</i> , 2005, 19, 631-642.	4.5	401
137	Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1. <i>Molecular and Cellular Endocrinology</i> , 2005, 229, 161-173.	1.6	106
138	Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1. <i>Cell</i> , 2005, 122, 33-43.	13.5	1,208
139	p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells. <i>Cancer Research</i> , 2003, 63, 4322-6.	0.4	31
140	Estrogen/Estrogen Antagonist Regulation of the Cell Cycle in Breast Cancer Cells. , 2002, , 57-71.		0
141	Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. <i>Cancer Research</i> , 2002, 62, 3126-31.	0.4	61
142	Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. <i>Cancer Research</i> , 2002, 62, 6916-23.	0.4	79
143	A Low Abundance Pool of Nascent p21WAF1/Cip1 Is Targeted by Estrogen to Activate Cyclin E-Cdk2. <i>Journal of Biological Chemistry</i> , 2001, 276, 45433-45442.	1.6	26
144	A Pure Estrogen Antagonist Inhibits Cyclin E-Cdk2 Activity in MCF-7 Breast Cancer Cells and Induces Accumulation of p130-E2F4 Complexes Characteristic of Quiescence. <i>Journal of Biological Chemistry</i> , 2000, 275, 38221-38229.	1.6	126